Biotech Values

[DewDiligence]

YMI—Would the fact that Biocon is marketing Nimo change your opinion?

Regardless of who’s involved, the business proposition for another Erbitux-like drug that reaches the major markets in the second half of the current decade is not especially compelling, IMO. By then, there will likely be one or more Erbitux biosimilars on the market, making it harder for an NME like Nimo to garner a premium price. Moreover, the Kras biomarker appears to have reduced rather than increased the demand for this class of drugs.